FibroGen (FGEN) Scheduled to Post Earnings on Monday

FibroGen (NASDAQ:FGENGet Rating) will issue its quarterly earnings data after the market closes on Monday, May 9th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

FibroGen (NASDAQ:FGENGet Rating) last announced its earnings results on Monday, February 28th. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.77). The firm had revenue of $16.54 million during the quarter, compared to analyst estimates of $47.65 million. FibroGen had a negative net margin of 123.25% and a negative return on equity of 93.23%. The firm’s revenue for the quarter was down 74.5% compared to the same quarter last year. During the same period last year, the company earned ($0.64) earnings per share. On average, analysts expect FibroGen to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of NASDAQ FGEN opened at $9.30 on Monday. FibroGen has a 52-week low of $9.26 and a 52-week high of $30.12. The business has a 50-day moving average price of $12.36 and a 200 day moving average price of $13.13. The stock has a market cap of $864.92 million, a PE ratio of -2.96 and a beta of 0.79.

A number of analysts have weighed in on FGEN shares. The Goldman Sachs Group decreased their price objective on FibroGen from $10.00 to $9.00 and set a “sell” rating for the company in a research report on Tuesday, March 1st. StockNews.com started coverage on FibroGen in a research report on Thursday, March 31st. They set a “hold” rating for the company. Finally, Zacks Investment Research raised FibroGen from a “strong sell” rating to a “hold” rating in a research report on Thursday, March 3rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, FibroGen has an average rating of “Hold” and an average price target of $20.43.

Hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its stake in shares of FibroGen by 10.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 610,516 shares of the biopharmaceutical company’s stock worth $8,609,000 after buying an additional 58,693 shares in the last quarter. UBS Group AG raised its stake in shares of FibroGen by 748.4% during the 3rd quarter. UBS Group AG now owns 305,882 shares of the biopharmaceutical company’s stock worth $3,126,000 after buying an additional 269,830 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of FibroGen by 1.8% during the 4th quarter. California State Teachers Retirement System now owns 116,903 shares of the biopharmaceutical company’s stock worth $1,648,000 after buying an additional 2,048 shares in the last quarter. Barclays PLC raised its stake in shares of FibroGen by 189.6% during the 4th quarter. Barclays PLC now owns 104,521 shares of the biopharmaceutical company’s stock worth $1,474,000 after buying an additional 68,424 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in shares of FibroGen by 57.4% during the 4th quarter. Parametric Portfolio Associates LLC now owns 98,081 shares of the biopharmaceutical company’s stock worth $1,383,000 after buying an additional 35,752 shares in the last quarter. 77.35% of the stock is owned by institutional investors and hedge funds.

About FibroGen (Get Rating)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Recommended Stories

Earnings History for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.